Global Anti Obesity Drugs Market

Global Anti Obesity Drugs Market Size, Share, Growth Analysis, By Type(Prescription Drugs, OTC Drugs), By Distribution channel(Hospital Pharmacy, Retail Pharmacy) - Industry Forecast 2024-2031

Report ID: SQMIG35D2060 | Region: Global | Published Date: April, 2024
Pages: 165 | Tables: 62 | Figures: 75

Global Anti Obesity Drugs Market Insights

Anti Obesity Drugs Market size was valued at USD 1.9 billion in 2019 and is poised to grow from USD 2.82 billion in 2023 to USD 13.26 billion by 2031, growing at a CAGR of 24.6% in the forecast period (2024-2031).

The World Obesity Federation predicts that by the end of 2025, the global cost of obesity would have increased by over 50%, or by around US$ 1.2 trillion. Therefore, the main objective of pharmaceutical companies at the moment is to create mitigation methods to lessen the burden and shrink the fat population. Additionally, the industry is expected to present tremendous prospects for new companies because of the growing patient population and low treatment rates. Additionally, the introduction of initiatives to educate people about obesity and the development of reimbursement policies are projected to fuel product demand during the projection period.

Due to a spike in the sales of approved pharmaceuticals for the COVID-19 emergency, the COVID-19 pandemic has had a favorable effect on the world market for anti-obesity medications. Additionally, pharmaceutical firms are putting a lot of effort into keeping the pandemic's supply and demand in check in order to sustain their profits. Due to their increased risk of developing the disease, health organizations have released the essential guidelines and recommendations for the management of overweight and obese patients in the COVID-19 era. Furthermore, the widespread application of strict lockdown measures has led to a sedentary lifestyle and a work-from-home environment that have both contributed to weight increase. During the pandemic, this is projected to have a higher effect on the sales of drugs for treating obesity.

US Anti Obesity Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Anti Obesity Drugs Market size was valued at USD 1.9 billion in 2019 and is poised to grow from USD 2.82 billion in 2023 to USD 13.26 billion by 2031, growing at a CAGR of 24.6% in the forecast period (2024-2031).

The top players are concentrated on inorganic expansion tactics such as teaming up with successful individuals and national initiatives or programmes that advertise their goods. As a result, these brands are known earlier than other brands in the industry under investigation. Due to the disease's great prevalence, there is moderate to intense intergroup conflict. 'Novo Nordisk A/S', 'Eisai Co., Ltd.', 'Arena Pharmaceuticals, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Orexigen Therapeutics, Inc.', 'Takeda Pharmaceutical Company Limited', 'Zafgen, Inc.', 'Norgine B.V.', 'GlaxoSmithKline plc', 'Boehringer Ingelheim International GmbH', 'Pfizer Inc.', 'Sanofi S.A.', 'Merck & Co., Inc.', 'VIVUS, Inc.', 'Johnson & Johnson', 'Teva Pharmaceutical Industries Ltd.', 'Bristol-Myers Squibb Company', 'Abbott Laboratories', 'AstraZeneca plc', 'Bayer AG'

Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

The development of various possible therapeutic compounds that target both Type 2 diabetes mellitus and obesity has also become a major trend among companies competing in the anti-obesity industry. The rising prevalence of Type 2 diabetes and obesity is motivating manufacturers and researchers to develop medications that can treat both conditions. Therefore, it is anticipated that the rise in unhealthy eating patterns, sedentary lifestyles, and the obese population will propel market expansion throughout the forecast period.

The North American market has a value of US$ 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products. Due to its efforts in R&D for the creation of therapeutically effective medications, Europe currently occupies the second-place position in the market. Growth is anticipated during the projection period as a result of this as well as rising public awareness of the advantages of weight loss.

Anti Obesity Drugs Market size was valued at USD 1.9 billion in 2021 and is poised to grow from USD 2.82 billion in 2022 to USD 13.26 billion by 2030, growing at a CAGR of 24.6% in the forecast period (2023-2030).

The top players are concentrated on inorganic expansion tactics such as teaming up with successful individuals and national initiatives or programmes that advertise their goods. As a result, these brands are known earlier than other brands in the industry under investigation. Due to the disease's great prevalence, there is moderate to intense intergroup conflict. 'Novo Nordisk A/S', 'Eisai Co., Ltd.', 'Arena Pharmaceuticals, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Orexigen Therapeutics, Inc.', 'Takeda Pharmaceutical Company Limited', 'Zafgen, Inc.', 'Norgine B.V.', 'GlaxoSmithKline plc', 'Boehringer Ingelheim International GmbH', 'Pfizer Inc.', 'Sanofi S.A.', 'Merck & Co., Inc.', 'VIVUS, Inc.', 'Johnson & Johnson', 'Teva Pharmaceutical Industries Ltd.', 'Bristol-Myers Squibb Company', 'Abbott Laboratories', 'AstraZeneca plc', 'Bayer AG'

Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

The development of various possible therapeutic compounds that target both Type 2 diabetes mellitus and obesity has also become a major trend among companies competing in the anti-obesity industry. The rising prevalence of Type 2 diabetes and obesity is motivating manufacturers and researchers to develop medications that can treat both conditions. Therefore, it is anticipated that the rise in unhealthy eating patterns, sedentary lifestyles, and the obese population will propel market expansion throughout the forecast period.

The North American market has a value of US$ 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products. Due to its efforts in R&D for the creation of therapeutically effective medications, Europe currently occupies the second-place position in the market. Growth is anticipated during the projection period as a result of this as well as rising public awareness of the advantages of weight loss.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Anti Obesity Drugs Market

Report ID: UCMIG35D2081 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

Dendritic Cell Cancer Vaccine Market
Buy Now GET FREE SAMPLE
Global Anti Obesity Drugs Market

Report ID: UCMIG35D2107 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

HLA Typing Market
Buy Now GET FREE SAMPLE
Global Anti Obesity Drugs Market

Report ID: UCMIG35D2101 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

Parkinson’s Disease Treatment Market
Buy Now GET FREE SAMPLE
Global Anti Obesity Drugs Market

Report ID: SQMIG35D2076 | Region: Global | Published Date: April, 2024 | Pages: 219 | Tables: 59 | Figures: 75

Global Cell Banking Outsourcing Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Anti Obesity Drugs Market

Product ID: SQMIG35D2060

$5,300
BUY NOW GET FREE SAMPLE